NCT01452373 - Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women | Biotech Hunter

Enrollment

238

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2013

Conditions

Vasomotor SymptomsHot Flushes

Interventions

DRUG

Placebo

Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.

DRUG

DHEA and Acolbifene

DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.

Trial Locations (15)

E2A 4X7

EndoCeutics site # 06, Bathurst

L7M 4Y1

EndoCeutics site # 70, Burlington

N0N 1G0

EndoCeutics site # 69, Corunna

N2G 1H6

EndoCeutics site # 73, Kitchener

N5Y 5K7

EndoCeutics site # 71, London

L3Y 5G8

EndoCeutics site # 72, Newmarket

N7T 4X3

EndoCeutics site # 68, Sarnia

J2B 7T1

EndoCeutics site # 04, Drummondville

H4N 3C5

EndoCeutics site # 12, Montreal

G1S 2L6

EndoCeutics site # 02, Québec

G1V 2L9

EndoCeutics site # 01, Québec

G6W 5M6

EndoCeutics site # 18, Saint Romuald

G9N 2H6

EndoCeutics site # 08, Shawinigan

J1H 1Z1

EndoCeutics site # 11, Sherbrooke

G6P 6P6

EndoCeutics site # 67, Victoriaville